Summary
88 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 101 USD is left as net profit.
- Revenue grew by 28% a year over the last 3 years.
- It earns 42 USD a year on every 100 USD of invested capital.
- It holds more cash than debt: $179.8M against $60.4M.
What to watch
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapPrice against the Bulios Fair Price
P/E against the industry (Biotechnology)
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 6.7 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 41% a year over 5 years. Over the last 3 years it grew by 28% a year. For the next fiscal year analysts expect revenue to grow by 17%.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 9.6 USD
- Research and development 13 USD
- Sales and administration 29 USD
- Taxes and other -52 USD
- Net profit 101 USD
Net profit, industry median (Biotechnology) 40 USD
Out of every 100 USD of revenue, 101 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 11
- Hold 4
- Sell 0
Today's price within the analysts' price targets
The average target of $16 is 2.2% below today's price. 73% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Product 96%
- License, Collaboration and Royalty Revenue 4.1%
By region
- UNITED STATES 93%
- JAPAN 6.8%
Product brings in 96% of revenue.
Segments in detail